CMS launched a voluntary payment model to expand Medicare coverage of GLP‑1 weight‑loss drugs, aiming to broaden beneficiary access while testing new payment and utilization rules. The program, announced by the agency, invites plans to participate under a framework tied to negotiated pricing and utilization criteria. Policymakers framed the move as a follow‑through on administration priorities to lower drug costs and widen access. Clarification: GLP‑1s are incretin‑based therapies originally for diabetes that have shown substantial weight‑loss effects and high demand.